Global Cell And Gene Therapy Market Size By Therapy Type (Cell Therapy, Gene Therapy), By Therapeutic Class (Cardiovascular Disease, Cancer), By Delivery Method (Vivo therapy, Ex Vivo therapy), By Geographic Scope and Forecast

<p>Cell And Gene Therapy Market size was valued at USD 26.59 Billion in 2023 and is projected to reach USD 116.71 Billion by 2031, growing at a CAGR of 22.40% from 2024 to 2031.</p>
<p>Key Market Drivers:<br />
• Growing Prevalence of Genetic Disorders: The increasing prevalence of hereditary and chronic disorders is a major driver of the cell and gene therapy business. As awareness and diagnosis improve, the need for effective treatment alternatives grows. For example, in October 2023, the World Health Organization emphasized the critical need for novel medicines for rare genetic disorders, urging nations to fund research in this field.<br />
• Increasing Government Investment: Governments worldwide are increasing their funding in biopharmaceutical research and development. In August 2023, the US National Institutes of Health launched a $100 million financing commitment to advance gene therapy research, particularly for uncommon disorders. This financial support improves research capacities and speeds up the development of novel medicines.<br />
• Technological Advancements: Gene editing technologies such as CRISPR and synthetic biology are advancing the possibilities of cell and gene therapies. Companies such as Editas Medicine, which announced a successful CRISPR trial for a genetic eye condition in September 2023, are propelling this trend forward, making medicines more precise and effective.<br />
• Increasing Industry Collaborations: Collaborations between pharmaceutical and biotech companies promote innovation and accelerate the development process. For example, in July 2023, Novartis announced a collaboration with a biotech startup to explore novel gene therapies, demonstrating a trend toward collaborative approaches to overcoming the hurdles of medication development.</p>